Therapy Areas: Central Nervous System
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
16 September 2026 - Skyhawk Therapeutics Inc, a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announced on Tuesday the final 15-month...
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
28 August 2026 - Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company based in Sydney, Australia, announced on Thursday new data showing that its lead asset, paxalisi...
Leal Therapeutics announces USD30m Series A extension and initiates Phase 1b/2a clinical trial of LTX-001 in schizophrenia
18 August 2026 - Leal Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics, announced on Monday a second close of USD30m of its Series A fina...
Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment
12 August 2026 - Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabol...
Insilico Medicine and CMS to collaborate further on CNS diseases
13 July 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Sunday that it has agreed an additional AI-empowered drug discovery collaboration with China Medical Syst...
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
10 July 2026 - Accord BioPharma, the US specialty division of India-based Intas Pharmaceuticals Ltd, focused on the development of oncology, immunology, and central nervous system (CNS) therapies, ann...